Last reviewed · How we verify
Paclitaxel loaded Polymeric micelle
At a glance
| Generic name | Paclitaxel loaded Polymeric micelle |
|---|---|
| Also known as | Genexol-PM® |
| Sponsor | Korean Breast Cancer Study Group |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (PHASE1, PHASE2)
- Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer
- A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib (PHASE2)
- Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer (PHASE2)
- Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (PHASE2)
- Paclitaxel-Avelumab for Angiosarcoma (PHASE2)
- Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas (PHASE2)
- A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |